Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hepatitis

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Native-like soluble E1E2 glycoprotein heterodimers on self-assembling protein nanoparticles for hepatitis C virus vaccine design.

Nature communications·2026

Same author

Substrate specificity in a designed RAS-targeting protease is coupled to active site and distal motions.

bioRxiv : the preprint server for biology·2026

Same author

Rational design of flavivirus E protein vaccine optimizes immunogenicity and mitigates antibody dependent enhancement risk.

Nature communications·2025

Same author

Macromolecular dimensions of a synthetic polyelectrolyte as a factor in its interactions with protein and cells: desirability for longer chains.

Journal of materials chemistry. B·2025

Same author

Polyphosphazene-Mediated Assembly of TLR4 and TLR7/8 Agonists Enables a Potent Nano-Adjuvant Delivery System for Hepatitis C Virus Vaccine Antigens.

Vaccines·2025

Same author

Cyclic Macromolecular Chains Visualized by Cryo-EM and AFM Reveal a Ring Expansion Polymerization Mechanism in a Classical Synthetic Pathway to Polyphosphazenes.

ACS macro letters·2025

Same journal

Oncogenic Viruses and Inhaled Microplastics: A Double Hit Hypothesis for Asthma Progression and Lung Cancer Development.

Reviews in medical virology·2026

Same journal

Dysregulated Metabolism in People Living With HIV in the Modern ART-Era: A Systematic Review of Targeted Metabolomics Studies.

Reviews in medical virology·2026

Same journal

From Norovirus to Andes Hantavirus: Indirect Viral Transmission and Emerging Prevention Strategies for Cruise Ship and Confined Environments.

Reviews in medical virology·2026

Same journal

Matrix Metalloproteinases and Viral Hepatitis: A Complex Interplay Driving Liver Fibrosis, Immune Dysregulation, and Hepatocarcinogenesis.

Reviews in medical virology·2026

Same journal

Kyasanur Forest Disease: Advances in Experimental Animal Models, Immune Assays, and Challenges in Vaccine Development.

Reviews in medical virology·2026

Same journal

A Cross-Country Evaluation of Respiratory Syncytial Virus and Human Metapneumovirus Surveillance Systems: Identifying Gaps and Best Practices for Improved Disease Monitoring.

Reviews in medical virology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 16, 2026

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods

Published on: May 11, 2018

Prospects for developing an Hepatitis C virus E1E2-based nanoparticle vaccine.

Eric A Toth¹, Alexander K Andrianov¹, Thomas R Fuerst^1,2

¹University of Maryland Institute for Bioscience and Biotechnology Research, Rockville, Maryland, USA.

Reviews in Medical Virology

|August 11, 2023

Summary

This summary is machine-generated.

Developing a Hepatitis C virus (HCV) vaccine requires eliciting broadly neutralizing antibodies. Nanoparticle vaccines offer a promising platform for delivering the E1E2 glycoprotein antigen, potentially overcoming limitations of traditional subunit vaccines.

Keywords:

HCV E1E2 nanoparticles nanoparticulate delivery systems vaccine

More Related Videos

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Related Experiment Videos

Last Updated: Jun 16, 2026

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods

Published on: May 11, 2018

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Area of Science:

Virology
Immunology
Vaccinology

Background:

Hepatitis C virus (HCV) chronically infects over 58 million globally, with 1.5 million new infections annually.
An effective HCV vaccine is a critical unmet medical and public health need due to rapid viral mutation.
Current vaccine candidates, primarily subunit vaccines using the E1E2 glycoprotein, struggle to induce robust, broadly neutralizing immune responses.

Purpose of the Study:

To review the potential of nanoparticle-based vaccines for Hepatitis C virus (HCV) using the E1E2 glycoprotein antigen.
To highlight the advantages of nanoparticle delivery systems for enhancing immunogenicity and immune cell interaction.
To identify and discuss challenges in incorporating E1E2 into nanoparticulate systems and potential solutions.

Main Methods:

Literature review of existing HCV vaccine research and antigen delivery platforms.
Analysis of nanoparticle vaccine technology and its application in vaccinology.
Discussion of antigen-antibody interactions and immune system engagement within nanoparticle systems.

Main Results:

Subunit vaccines have shown limited immunogenicity for HCV.
Nanoparticle vaccines offer controlled antigen presentation and enhanced lymph node trafficking.
Successful incorporation of E1E2 into nanoparticles requires addressing specific formulation and immunogenicity challenges.

Conclusions:

Nanoparticle-based E1E2 vaccines represent a promising strategy to overcome the limitations of current HCV vaccine candidates.
Further research is needed to optimize nanoparticle formulation and antigen incorporation for robust immune responses.
Addressing technical challenges is crucial for the successful clinical development of nanoparticle HCV vaccines.